MARKETS
Markets

Celularity To Begin U.S. Production Of MuseCell Innovations' Dezawa MuseCells At Its New Jersey Facility

Aug 27, 2026 · 09:03 AM ET· updated 57m ago

The initial program is designed to establish manufacturing capability for MCI-authenticated DMC preparations. Under the MCI platform, a preparation is authenticated as a DMC product through perinatal, bone marrow or

Share
Why It Matters

Celularity is starting to make a special type of cell medicine in New Jersey instead of somewhere else. This shows the company is growing and getting ready to sell more products, which is something to watch as a sign of whether their business plan is actually working.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.